Anti-ENA Abs (RDL)

The Anti-Extractable Nuclear Antigen Antibodies test (anti-ENA; anti-RNP) is used to assess systemic autoimmune connective tissue diseases and to support monitoring in established cases. It is often ordered as follow-up to a positive ANA to refine specificity for defined autoimmune syndromes. Within this panel, anti-Sm provides high specificity for systemic lupus erythematosus. Anti–U1 RNP is identified across a range of rheumatic conditions, and high titers are most strongly associated with mixed connective tissue disease. Findings inform diagnosis and longitudinal assessment when considered alongside other serologic results and the clinical picture.

Extractable nuclear antigen antibodies encompass a heterogeneous group of autoantibodies directed against nuclear and cytoplasmic ribonucleoprotein antigens. Clinically relevant specificities within this group include Sm and U1-RNP among others. Testing for ENA-class antibodies is typically pursued after a positive ANA to increase diagnostic specificity; however, a negative result does not exclude disease. Positive results require interpretation in clinical context because autoantibodies may appear before overt manifestations. Depending on the pattern of reactivity, confirmatory or more targeted methods (eg, immunoblot or antigen-specific assays) may be used.